MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 146356 | Name: Vatinoxan

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Vatinoxan is an α2-adrenoceptor antagonist primarily studied for its veterinary applications, particularly in combination with sedatives like medetomidine. It works by selectively blocking peripheral α2-adrenoceptors, which helps reduce the cardiovascular and gastrointestinal side effects commonly associated with α2-agonist sedatives. Unlike other antagonists, Vatinoxan does not significantly cross the blood-brain barrier, preserving central sedation while mitigating peripheral adverse effects.

Chemical Structure

Vatinoxan
Vatinoxan
CAS#114914-42-0

Theoretical Analysis

MedKoo Cat#: 146356

Name: Vatinoxan

CAS#: 114914-42-0

Chemical Formula: C20H26N4O4S

Exact Mass: 418.1675

Molecular Weight: 418.51

Elemental Analysis: C, 57.40; H, 6.26; N, 13.39; O, 15.29; S, 7.66

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Vatinoxan;
IUPAC/Chemical Name
N-(2-((2R,12bS)-2'-oxo-1,3,4,6,7,12b-hexahydrospiro[benzofuro[2,3-a]quinolizine-2,4'-imidazolidin]-3'-yl)ethyl)methanesulfonamide
InChi Key
GTBKISRCRQUFNL-OXJNMPFZSA-N
InChi Code
1S/C20H26N4O4S/c1-29(26,27)22-8-11-24-19(25)21-13-20(24)7-10-23-9-6-15-14-4-2-3-5-17(14)28-18(15)16(23)12-20/h2-5,16,22H,6-13H2,1H3,(H,21,25)/t16-,20+/m0/s1
SMILES Code
CS(=O)(=O)NCCN1C(=O)NC[C@]12CCN3CCC4=C(OC5=C4C=CC=C5)[C@@H]3C2
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 418.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Adam M, Lindén J, Raekallio M, Meller A, Mannerström B, Abu-Shahba A, Seppänen-Kaijansinkko R, Salla K. Effects of vatinoxan on xylazine-induced pulmonary alterations in sheep. J Vet Pharmacol Ther. 2022 Jan;45(1):117-125. doi: 10.1111/jvp.13013. Epub 2021 Sep 3. PMID: 34478172. 2: Pypendop BH, Ahokoivu H, Honkavaara J. Pharmacokinetics of vatinoxan in male neutered cats anesthetized with isoflurane. Vet Anaesth Analg. 2020 Jan;47(1):70-75. doi: 10.1016/j.vaa.2019.10.004. Epub 2019 Oct 24. PMID: 31806431. 3: Greunz EM, Limón D, Petersen RL, Raekallio MR, Grøndahl C, Bertelsen MF. The impact of vatinoxan on medetomidine-ketamine-midazolam immobilization in Patagonian maras (Dolichotis patagonum). Vet Anaesth Analg. 2021 May;48(3):372-379. doi: 10.1016/j.vaa.2020.08.012. Epub 2021 Feb 22. PMID: 33820746. 4: Einwaller J, Meyer LCR, Auer U, Raekallio M, Nowack J, Haw A, Vetter S, Painer J, Stalder G. Cardiovascular effects of intravenous vatinoxan in wild boars (Sus scrofa) anaesthetised with intramuscular medetomidine-tiletamine- zolazepam. Vet Rec. 2022 Jan;190(2):e835. doi: 10.1002/vetr.835. Epub 2021 Sep 1. PMID: 34472117. 5: Sainmaa S, Mykkänen A, Adam M, Jantunen N, Vainio O, Raekallio M. INTRAVENOUS VATINOXAN IN MARKHORS (CAPRA FALCONERI HEPTNERi) IMMOBILIZED WITH INTRAMUSCULAR MEDETOMIDINE AND KETAMINE-A PRELIMINARY DOSESCREENING STUDY. J Zoo Wildl Med. 2019 Mar 1;50(1):159-166. doi: 10.1638/2018-0030. PMID: 31120674. 6: Adam M, Lindén J, Raekallio M, Abu-Shahba A, Mannerström B, Seppänen- Kaijansinkko R, Meller A, Salla K. Concentrations of vatinoxan and xylazine in plasma, cerebrospinal fluid and brain tissue following intravenous administration in sheep. Vet Anaesth Analg. 2021 Nov;48(6):900-905. doi: 10.1016/j.vaa.2021.08.003. Epub 2021 Aug 28. PMID: 34561183. 7: Salla KM, Turunen HA, Kallio-Kujala IJ, Pekkola V, Casoni DC, Lepajoe J, Björkenheim P, Raekallio MR, Vainio O. Effects of vatinoxan in dogs premedicated with medetomidine and butorphanol followed by sevoflurane anaesthesia: a randomized clinical study. Vet Anaesth Analg. 2022 Nov;49(6):563-571. doi: 10.1016/j.vaa.2022.08.002. Epub 2022 Sep 8. PMID: 36115767. 8: Niemann L, Kutter AP, Joerger FB, Wieser ML, Hartnack S, Steblaj B. The impact of vatinoxan on microcirculation after intramuscular co-administration with medetomidine in Beagle dogs: a blinded crossover study. Vet Anaesth Analg. 2022 Jul;49(4):336-343. doi: 10.1016/j.vaa.2021.07.007. Epub 2022 Jan 7. PMID: 35459629. 9: Verhaar N, Kopp V, Pfarrer C, Neudeck S, König K, Rohn K, Kästner S. Alpha2 Antagonist Vatinoxan Does Not Abolish the Preconditioning Effect of Dexmedetomidine on Experimental Ischaemia-Reperfusion Injury in the Equine Small Intestine. Animals (Basel). 2023 Aug 30;13(17):2755. doi: 10.3390/ani13172755. PMID: 37685019; PMCID: PMC10486550. 10: Einwaller J, Painer J, Raekallio M, Gasch K, Restitutti F, Auer U, Stalder GL. Cardiovascular effects of intravenous vatinoxan (MK-467) in medetomidine- tiletamine-zolazepam anaesthetised red deer (Cervus elaphus). Vet Anaesth Analg. 2020 Jul;47(4):518-527. doi: 10.1016/j.vaa.2019.10.011. Epub 2020 Mar 29. PMID: 32507716. 11: Tapio H, Raekallio MR, Mykkänen A, Männikkö S, Scheinin M, Bennett RC, Vainio O. Effects of vatinoxan on cardiorespiratory function and gastrointestinal motility during constant-rate medetomidine infusion in standing horses. Equine Vet J. 2019 Sep;51(5):646-652. doi: 10.1111/evj.13085. Epub 2019 Mar 14. PMID: 30793362; PMCID: PMC6767159. 12: Lindh E, Meller A, Raekallio M. Effects of vatinoxan in rats sedated with a combination of medetomidine, midazolam and fentanyl. Acta Vet Scand. 2024 May 31;66(1):23. doi: 10.1186/s13028-024-00744-y. PMID: 38822394; PMCID: PMC11141047. 13: Pypendop BH, Ahokoivu H, Honkavaara J. Pharmacokinetics of dexmedetomidine during administration of vatinoxan in male neutered cats anesthetized with isoflurane. J Vet Pharmacol Ther. 2020 Jan;43(1):1-5. doi: 10.1111/jvp.12796. Epub 2019 Jul 18. PMID: 31318080. 14: Hector RC, Rezende ML, Mama KR, Steffey EP, Raekallio MR, Vainio OM. Combined effects of dexmedetomidine and vatinoxan infusions on minimum alveolar concentration and cardiopulmonary function in sevoflurane-anesthetized dogs. Vet Anaesth Analg. 2021 May;48(3):314-323. doi: 10.1016/j.vaa.2020.12.007. Epub 2021 Feb 2. PMID: 33678575. 15: Jeffrey A, Burns L, Santangelo S, Sallaberry-Pincheira N, Camlic S, Paredes B, Barletta M, Divers S. Medetomidine-vatinoxan-midazolam provides similar sedation depth with reduced bradycardia compared to dexmedetomidine-midazolam in pigeons (Columba livia domestica). Am J Vet Res. 2024 Aug 9;85(10):ajvr.24.05.0143. doi: 10.2460/ajvr.24.05.0143. PMID: 39127079. 16: Roug A, Smith C, Raath JP, Meyer LR, Laubscher LL. CARDIORESPIRATORY EFFECTS OF VATINOXAN IN BLESBOK (DAMALISCUS PYGARGUS PHILLIPSI) IMMOBILIZED WITH THIAFENTANIL-MEDETOMIDINE. J Zoo Wildl Med. 2024 Sep;55(3):704-712. doi: 10.1638/2023-0066. PMID: 39255211. 17: Huuskonen V, Restitutti F, Raekallio M, Honkavaara J, Pesonen T, Vainio O. Cardiovascular effects of dobutamine, norepinephrine and phenylephrine in isoflurane-anaesthetized dogs administered dexmedetomidine-vatinoxan. Vet Anaesth Analg. 2022 Nov;49(6):546-555. doi: 10.1016/j.vaa.2022.07.007. Epub 2022 Jul 31. PMID: 36058821. 18: Turunen H, Raekallio M, Honkavaara J, Jaakkola J, Scheinin M, Männikkö S, Hautajärvi H, Bennett R, Vainio O. Effects of intramuscular vatinoxan (MK-467), co-administered with medetomidine and butorphanol, on cardiopulmonary and anaesthetic effects of intravenous ketamine in dogs. Vet Anaesth Analg. 2020 Sep;47(5):604-613. doi: 10.1016/j.vaa.2020.05.008. Epub 2020 Jun 11. PMID: 32682664. 19: Jaeger AT, Pypendop BH, Ahokoivu H, Honkavaara J. Cardiopulmonary effects of dexmedetomidine, with and without vatinoxan, in isoflurane-anesthetized cats. Vet Anaesth Analg. 2019 Nov;46(6):753-764. doi: 10.1016/j.vaa.2019.05.012. Epub 2019 Jun 17. PMID: 31416697. 20: Honkavaara JM, Raekallio MR, Syrja PM, Pypendop BH, Knych HK, Kallio-Kujala IJ, Vainio OM. Concentrations of medetomidine enantiomers and vatinoxan, an α2-adrenoceptor antagonist, in plasma and central nervous tissue after intravenous coadministration in dogs. Vet Anaesth Analg. 2020 Jan;47(1):47-52. doi: 10.1016/j.vaa.2019.07.004. Epub 2019 Aug 29. PMID: 31761600.